Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-12 and Interferon Alfa-2b in Metastatic Melanoma
NCT00026143Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2001
- Primary completion
- Jul 2004
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant interleukin-12 in melanoma, sponsored by National Cancer Institute. Primary endpoints: Clinical Response Rate up to 2 years and Progression-Free Survival up to 2 years. Started Oct 2001; status: completed.
02
Drugs
recombinant interleukin-12
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00026143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026143.